Fig. 4From: Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysisForest plot for the subgroup analysis of risk of MACE in patients assigned to prasugrel or ticagrelor as compared with clopidogrel on the basis of GPI: stratified according to the follow-up durationBack to article page